monocytic leukemia (AML) cell line
RPMI-1640 medium was developed by Moore et al., at Roswell Park Memorial Institute, hence the acronym RPMI. The formulation is based on the RPMI-1630 series of media utilizing a bicarbonate buffering system and alterations in the amounts of amino acids and vitamins. RPMI-1640 medium has been used for the culture of human normal and neoplastic leukocytes. RPMI-1640 when properly supplemented, has demonstrated wide applicability for supporting growth of many types of cell cultures, including fresh human lymphocytes in the 72-hour phytohemagglutinin (PHA) stimulation assay.There are a variety of formulations:12-702 - with L-glutamineBE12-702/U1 - with UltraGlutamineIBE15-702D - [powder] with L-glutamine12-167 - without L-glutamine12-115 - with L-glutamine and 25 mM HEPES bufferBE12-115/U1 - with UltraGlutamineI and 25 mM HEPES buffer04-525 - with L-glutamine and 165 nM MOPS (used for some mycological assays)09-774 - with L-glutamine, 25 mM HEPES buffer 100 units/ml penicillin, 50 ug/ml streptomycin12-918 - without L-glutamine or phenol redBE12-752 - with L-glutamine, without D-glucoseStorage = 2ºC to 8ºC (versions without L-glutamine and those with UltraGlutamine can be stored at 15ºC to 30ºC)
Privacy | Legal | About Lonza
©2019 Lonza. All rights reserved.